

Board of Directors Meeting in Public - Cover Sheet

Subject:	Research and Development Performance Report – 2021/22	Date: 5th May 2022		
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	Elizabeth Gemmill, Research and Innovation Director			
Presented By:	Alison Steel, Head of Research and Innovation			
Purpose				
To present the Research and Innovation Annual Performance Report		Approval		
		Assurance	X	
Update and assurance on performance KPI's and financial position		Update		
Update on recovery and growth of the SFH research portfolio		Consider		
Strategic Objectives				
To provide outstanding care	To promote and support health and wellbeing	To maximise the potential of our workforce	To continuously learn and improve	To achieve better value
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Confirmed £755,435.10 EMCRN 2022/23 budget – rollover, no enhancements Commercial income in 21/22 for re-investment - £164,088.11 			
Patient Impact	<ul style="list-style-type: none"> 1471 participants recruited into research studies, 853 in to UPH studies 			
Staff Impact	<ul style="list-style-type: none"> Collaboration with Nottingham Trent University to support development of clinical academic careers and research exposure for clinical staff 			
Services	<ul style="list-style-type: none"> Support Clinical Divisions with research engagement CRF estate secured 			
Reputational	<ul style="list-style-type: none"> Retain a strong reputation for research delivery, re set and recovery Leading the way with collaboration with GP practises, HEI's and other NHS organisations to increase Research opportunities Leading on multi-site clinical trial 			
Committees/groups where this item has been presented before				
None				
Executive Summary				
Performance Metrics				
<ul style="list-style-type: none"> 1471 participants recruited into research studies compared to 3054 in 20/21, 64 studies on the SFH portfolio Confirmed £755,435.10 EMCRN 2022/23 budget. Commercial income at £164,088.11 				
Patient Experience				
<ul style="list-style-type: none"> 91% of participants Agree/Strongly Agree their participation in Research has been valued 93% of participants would consider taking part in Research again All Participants Agree/Strongly Agree that they have been treated with courtesy and respect 				

Research highlights 21-22

1. Post pandemic renewed government commitment to support health and care research
2. CRF space secured
3. Leading Research – Chief Investigator and Sponsor for a grant funded multi-site study
4. Influencing and informing through the Nottinghamshire ICS Research Partners Group
5. Working across boundaries - Joint Senior Research Nurse post across primary care and SFH post active
6. Development of formal partnership with NTU
7. Inclusion in NUH successful CRF re bidding and plans for mobile research unit